Clinical Trials
12 articles in the Clinical Trials category
Meant Launches LegitScript-Certified GLP-1 Telehealth Platform with Coaching
Meant has introduced a new telehealth platform for GLP-1 therapies that has earned LegitScript certification. The platform combines medical oversight with personalized coaching to support patients using GLP-1 medications. This launch marks a step forward in integrating digital health services with weight management treatments.
5 min read
Arch Biopartners Expands LSALT Peptide Trial to US Sites
Arch Biopartners has announced plans to expand its clinical trial of the LSALT peptide into the United States. The move extends the company's research into the peptide's potential therapeutic applications. Details of the expansion were reported on August 12, 2026.
5 min read
Why Big Pharma Avoids Unapproved Peptide Investments
A recent report from the Australian Financial Review explores why major pharmaceutical companies have not committed funding to unapproved peptides. The article examines the regulatory, scientific, and commercial barriers that keep big pharma on the sidelines. It highlights the cautious approach of the industry toward these compounds.
5 min readRetatrutide and Erectile Dysfunction: What the Evidence Shows
A report titled "Does Retatrutide Cause Erectile Dysfunction?" from FC Bayern, dated August 1, 2026, addresses a common question about the investigational obesity drug. The article, categorized under Clinical Trials, examines whether retatrutide is linked to erectile dysfunction. It provides a focused overview of the concern without presenting new clinical data.
5 min read
Time to Minimum C-Peptide May Predict T1D Treatment Response
A new study suggests that the time it takes for residual C-peptide levels to reach a minimum after diagnosis may serve as a predictor of treatment efficacy in type 1 diabetes. The finding could help clinicians identify patients most likely to benefit from early interventions.
2 min readECO 2026: ATTAIN-MAINTAIN Trial Shows Orforglipron in Sustained Weight Loss
The ATTAIN-MAINTAIN trial at ECO 2026 demonstrates orforglipron's effectiveness for sustained weight loss. This presentation highlights the drug's specific role in weight management. Findings from the trial focus on achieving and keeping weight loss over time.
2 min read
Survodutide Shows Renal and Metabolic Gains in DKD Mouse Model at ECO 2026
Researchers presented data at the European Congress on Obesity (ECO) on survodutide's effects in a mouse model of advanced diabetic kidney disease (DKD). The drug improved kidney injury markers like albuminuria and glomerulosclerosis, along with metabolic measures such as body weight and glucose levels. These results suggest potential for broader applications if confirmed in human studies.
2 min read
Orforglipron Maintains Weight Loss After Stopping Injections
Results from the ATTAIN-MAINTAIN trial show that orforglipron pills helped patients keep most of their weight loss after stopping injectable tirzepatide or semaglutide. Participants switching to the daily oral GLP-1 maintained far more weight reduction than those on placebo. The study involved 376 US patients previously treated with injections for over a year.
3 min readAdults Retain Most Weight Loss After Switching to Foundayo
Adults who switched from an injectable drug to Foundayo maintained the majority of their weight loss. This outcome shows patients can preserve a substantial portion of prior weight reduction following the change in treatment. The results point to Foundayo's role in sustaining weight management after injectable use.
2 min readStudy: Orforglipron Maintains Most Weight Loss from Injectables
A study demonstrates that patients retain most weight loss from injectable obesity drugs after switching to orforglipron. This research confirms the medication's role in preserving treatment outcomes. The findings support transition strategies for obesity management.
2 min readOrforglipron and Probiotic Aid Weight Loss Maintenance in Obesity
Two independent clinical trials demonstrate that the drug orforglipron helps patients with obesity keep their weight loss. A probiotic supplement provides similar benefits for weight maintenance in this group. These results highlight options for sustaining weight reduction.
2 min readOrforglipron Tested in Phase 3b ATTAIN-MAINTAIN Weight Trial
A double-blind, randomized phase 3b trial called ATTAIN-MAINTAIN examined orforglipron for maintaining body weight reduction. The study appears in Nature. This research focuses on sustaining weight loss achieved earlier.
2 min readOther categories